Stay updated with breaking news from Oncology Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In an 11-to-1 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the proposed indication of olaparib in combination with abiraterone acetate and prednisone or prednisolone for the initial treatment of patients with metastatic castration-resistant prostate cancer should be restricted to those whose tumors harbor a BRCA mutation.
First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9%... | April 27, 2023
Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.
The American College of Cardiology will host the annual Advancing the Cardiovascular Care of the Oncology Patient course on April 14-16, 2023, in Washington, DC.
An international group of researchers, led by Dr. José Ángel Martínez-Climent at the Cima University of Navarra (Spain), has created mouse avatars of patients with multiple myeloma to study and develop personalized treatments against this blood cancer, the second most frequent hematological cancer and incurable in most cases. These artificial mice can mimic the genetic and immunological diversity of the origin and evolution of this disease in patients. This advance will allow researchers to design more effective and personalized therapies for multiple myeloma. Nature Medicine publishes this...